Making ideas work for a better world
Bench to Bedside
Discover the University of Edinburgh’s world leading therapeutic expertise.
Explore how you can work with us as we open our doors to a campus that gives you full access to our academic researchers, patients, clinicians, scientists, partners and state of the art clinical and pre-clinical research facilities that can help you develop innovative ideas to deliver solutions to the world’s biggest medical challenges.
Edinburgh Innovations is the University of Edinburgh’s commercialisation service. We bring University of Edinburgh research to industry, working to identify ideas with value, and facilitating the process of bringing them to life in real-world applications.
We make ideas work for a better world.
Join the conversation to stay up to date with the latest advances in research, news and events, all designed to help your business deliver solutions to the world’s biggest challenges.
Collaborative research in predictive biomarkers
Investing in innovation, from bench to bedside
Bench to bedside: with industry all the way
Collaboration, Diversity and Impact from Bench to Bedside
Macomics: outsmarting cancer
Professor Neil Henderson on developing therapies for liver disease
Pheno Therapeutics: a perfect partnership
Professor Jonathan Fallowfield tackles liver disease
Dr Luca Cassetta's innovation journey
Professor Neil Carragher's innovation journey
Discover our facilities
Discover the University of Edinburgh’s world class facilities that can support your projects from Bench to Bedside.
Edinburgh Clinical Trials Unit (ECTU), underpinned by research governance, provides expert support to develop, design and deliver world-class clinical trials. The Unit provides trial management, medical statistics and data management. Strong links with NHS Lothian allows access to curated patient data sets for research purposes.
Expert facilites for Healthcare and Disease Management, Pharmaceuticals and Medical Biotechnology,
Life Sciences and Biotechnology, Food and Drink, Agri-Tech, Agri-Food and Plant Biology.
Discover our people
Discover the University of Edinburgh’s innovative therapeutic capability led by an exceptional team.
Emily is the convenor of CAMARADES – a research group set up to improve translation from preclinical research to the clinic and winner of the 2021 British Neuroscience Association Credibility Prize.
Discover how we can help you develop innovative ideas to deliver solutions to the world’s biggest medical problems
Dr Andrea Taylor
Head of Business Development, College of Medicine and Veterinary Medicine
Our track record
Discover our spinout successes. Edinburgh Innovations has supported five therapeutics spinouts over the last year alone, securing £38m of investment.
Cancer cells evade destruction by the immune system, and tumour associated macrophages (TAMs) are a key component of this immuno-suppressive and pro-tumoral ecosystem. The ability to modulate TAMs would alter the tumour microenvironment and thus enhance the body’s ability to fight cancer.
Professor Jeffrey Pollard is a pioneer of the study of TAMs and his research team was the first to demonstrate that they promote tumour progression and malignancy. The ground-breaking research he was conducting attracted future Macomics co-founder Dr Luca Cassetta.
Pheno Therapeutics exploits the clinical insight and vast drug discovery expertise of its two distinguished founders: phenotypic screening pioneer Professor Neil Carragher and world-leading regenerative neurology specialist, Professor Sidharthan Chandran, Director of both Edinburgh Neuroscience and the Anne Rowling Regenerative Neurology Clinic.
By utilising Professor Carragher’s Phenomics Drug Discovery (PDD) platform, and using a unique human stem cell model to identify novel remyelinating agents, the company aims to develop transformational therapeutics that repair damaged myelin sheaths, thus reversing the effects of the disease and significantly improving quality of life for MS patients.
Euan’s concept became a collaborative research project between the Euan Macdonald Centre and the University of Edinburgh Centre for Speech Technology Research, led by Alice Smith and based at the Anne Rowling Regenerative Neurology Clinic.
The team accessed world class facilities across the School of Medicine and the School of Informatics.
In 2019 SpeakUnique became a University spinout. By creating a synthetic version of an individual’s voice, or repairing voices that are becoming unclear, users can “speak” in a voice that is identifiably their own.
Based in the University’s world-class facilities at the Centre for Regenerative Medicine his team has manufactured and filed several foundational patent applications.
As a result of these discoveries Professor Forbes co-founded Resolution Therapeutics which, last year, received £26.6m from specialist healthcare investment company Syncona Ltd.
Backed by Syncona, Resolution are now harnessing the healing power of the macrophage to develop a novel and transformational therapeutic product that will effectively treat patients suffering from chronic liver disease and help them avoid the need for a transplant.